- Conditions
- Sexual Dysfunction, Physiological
- Interventions
- Testosterone Cream, Estring
- Drug
- Lead sponsor
- University of California, San Francisco
- Other
- Eligibility
- 18 Years to 80 Years · Female only
- Enrollment
- 76 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2012
- U.S. locations
- 1
- States / cities
- San Francisco, California
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1345–1368
of 17,274
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Eosinophilic Esophagitis
- Interventions
- AQ280 Capsule, AQ280 Tablet for Oral Suspension, Placebo Capsule, Placebo Tablet for Oral Suspension
- Drug
- Lead sponsor
- AQILION AB
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 9 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2025
- U.S. locations
- 1
- States / cities
- Madison, Wisconsin
- Conditions
- Small Cell Lung Carcinoma, Stage IV Lung Cancer AJCC v8, Stage IVA Lung Cancer AJCC v8, Stage IVB Lung Cancer AJCC v8
- Interventions
- Gemcitabine, Nivolumab
- Drug · Biological
- Lead sponsor
- Wake Forest University Health Sciences
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 14 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2022
- U.S. locations
- 1
- States / cities
- Winston-Salem, North Carolina
- Conditions
- Crohn Disease
- Interventions
- Allogeneic Bone Marrow Transplantation, Cyclophosphamide, Fludarabine Phosphate, Laboratory Biomarker Analysis, Mycophenolate Mofetil, Mycophenolic Acid, Quality-of-Life Assessment, Tacrolimus, Total-Body Irradiation
- Procedure · Drug · Other + 1 more
- Lead sponsor
- Fred Hutchinson Cancer Center
- Other
- Eligibility
- 18 Years to 60 Years
- Enrollment
- 2 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2019
- U.S. locations
- 1
- States / cities
- Seattle, Washington
- Conditions
- Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Precancerous Condition, Secondary Myelofibrosis
- Interventions
- Busulfan, Cytarabine, Fludarabine phosphate, mycophenolate mofetil, tacrolimus, allogeneic hematopoietic stem cell transplantation, umbilical cord blood transplantation, total-body irradiation
- Drug · Procedure · Radiation
- Lead sponsor
- Barbara Ann Karmanos Cancer Institute
- Other
- Eligibility
- Up to 69 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2015
- U.S. locations
- 1
- States / cities
- Detroit, Michigan
- Conditions
- Advanced Cancer
- Interventions
- RDEA119, Sorafenib
- Drug
- Lead sponsor
- Bayer
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 62 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2012
- U.S. locations
- 9
- States / cities
- Los Angeles, California • Las Vegas, Nevada • Albany, New York + 6 more
- Conditions
- Anatomic Stage IV Breast Cancer AJCC v8, Castration-Resistant Prostate Carcinoma, Stage IVB Prostate Cancer AJCC v8
- Interventions
- Biopsy, Biospecimen Collection, Computed Tomography, Magnetic Resonance Imaging, Magrolimab, Olaparib
- Procedure · Biological · Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2026
- U.S. locations
- 5
- States / cities
- Costa Mesa, California • Orange, California • The Bronx, New York + 1 more
- Conditions
- Stage III Non-small Cell Lung Cancer
- Interventions
- Chemotherapy following concurrent Chemoradiotherapy
- Drug
- Lead sponsor
- Syed Jafri
- Other
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2013
- U.S. locations
- 1
- States / cities
- Shreveport, Louisiana
- Conditions
- Lymphoma, Leukemia
- Interventions
- CPI-613
- Drug
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- 12 Years and older
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2026
- U.S. locations
- 11
- States / cities
- Duarte, California • Boston, Massachusetts • Basking Ridge, New Jersey + 8 more
- Conditions
- Port Wine Stains
- Interventions
- Rapamycin cream, Pulsed dyed laser
- Drug · Procedure
- Lead sponsor
- AFT Pharmaceuticals, Ltd.
- Industry
- Eligibility
- Up to 10 Years
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2027
- U.S. locations
- 1
- States / cities
- Corpus Christi, Texas
- Conditions
- Melanoma Stage III, Melanoma Stage IV
- Interventions
- Binimetinib, Imatinib
- Drug
- Lead sponsor
- University of California, San Francisco
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 25 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2028
- U.S. locations
- 2
- States / cities
- La Jolla, California • San Francisco, California
- Conditions
- Prostate Cancer
- Interventions
- bevacizumab, prostatic acid phosphatase-sargramostim fusion protein, sipuleucel-T, therapeutic autologous dendritic cells, in vitro-treated peripheral blood stem cell transplantation
- Biological · Procedure
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- Male only
- Enrollment
- 25 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2001
- U.S. locations
- 1
- States / cities
- San Francisco, California
- Conditions
- Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma
- Interventions
- Bortezomib, Daratumumab, Dexamethasone, Venetoclax
- Drug · Biological
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2020
- U.S. locations
- 3
- States / cities
- Indianapolis, Indiana • Rochester, Minnesota • Wauwatosa, Wisconsin
- Conditions
- Prostatic Neoplasms
- Interventions
- Pembrolizumab, Docetaxel, Prednisone, Placebo, Dexamethasone
- Biological · Drug
- Lead sponsor
- Merck Sharp & Dohme LLC
- Industry
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 1,030 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2023
- U.S. locations
- 28
- States / cities
- Mobile, Alabama • Fullerton, California • Los Angeles, California + 24 more
- Conditions
- Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS), Hematopoietic Stem Cell Transplant (HSCT)
- Interventions
- Reduced-Intensity Conditioning Regimen, Myeloablative Conditioning Regimen
- Drug
- Lead sponsor
- Randy Windreich
- Other
- Eligibility
- 0 Months to 26 Years
- Enrollment
- 21 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2023
- U.S. locations
- 1
- States / cities
- Pittsburgh, Pennsylvania
- Conditions
- Endometrial Cancer
- Interventions
- raloxifene
- Drug
- Lead sponsor
- Northwestern University
- Other
- Eligibility
- 18 Years and older · Female only
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1998 – 2000
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
- Conditions
- Esophageal Cancer, Gastroesophageal Cancer
- Interventions
- 5-Fluorouracil, Oxaliplatin, Radiation Therapy, Surgery
- Drug · Radiation · Procedure
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 18 Years to 76 Years
- Enrollment
- 126 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2013
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Alzheimer Disease
- Interventions
- Educational Materials
- Other
- Lead sponsor
- University of Massachusetts, Worcester
- Other
- Eligibility
- 50 Years and older
- Enrollment
- 11,375 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2026
- U.S. locations
- 1
- States / cities
- Worcester, Massachusetts
- Conditions
- Relapsed or Refractory (r/r) B-cell Non-Hodgkin Lymphoma (NHL)
- Interventions
- TAK-007, Chemotherapy Agents
- Biological · Drug
- Lead sponsor
- Takeda
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 27 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2038
- U.S. locations
- 15
- States / cities
- Birmingham, Alabama • Los Angeles, California • Washington D.C., District of Columbia + 12 more
- Conditions
- Primary Invasive Malignant Neoplasm of Female Breast, Carcinoma Breast, Breast Cancer Female, Carcinoma, Ductal, Breast, Stage II Breast Cancer, Stage I Breast Cancer, Stage III Breast Cancer
- Interventions
- Investigational Imaging device, AVB-620
- Device · Drug
- Lead sponsor
- Avelas Biosciences, Inc.
- Industry
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 92 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2020
- U.S. locations
- 13
- States / cities
- San Diego, California • Washington D.C., District of Columbia • Jacksonville, Florida + 10 more
- Conditions
- Acne Vulgaris
- Interventions
- S6G5T-3, S6G5T-1, S6G5T-5, S6G5T-6, S6G5T-7, S6G5T-8
- Drug
- Lead sponsor
- Sol-Gel Technologies, Ltd.
- Industry
- Eligibility
- 9 Years and older
- Enrollment
- 726 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2017
- U.S. locations
- 34
- States / cities
- Anaheim, California • Cerritos, California • Chula Vista, California + 27 more
- Conditions
- Clear Cell Sarcoma
- Interventions
- AMG 337
- Drug
- Lead sponsor
- NantPharma, LLC
- Industry
- Eligibility
- 16 Years and older
- Enrollment
- 8 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2021
- U.S. locations
- 2
- States / cities
- El Segundo, California • Houston, Texas
- Conditions
- Adenocarcinoma, Carcinoma, Pancreatic Ductal
- Interventions
- Relacorilant, Nab-paclitaxel, Gemcitabine
- Drug
- Lead sponsor
- Corcept Therapeutics
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 80 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2027
- U.S. locations
- 20
- States / cities
- Scottsdale, Arizona • Los Angeles, California • Orange, California + 16 more
- Conditions
- Advanced Prostate Adenocarcinoma With Neuroendocrine Differentiation, Castration-Resistant Prostate Carcinoma, Metastatic Prostate Adenocarcinoma With Neuroendocrine Differentiation, Metastatic Prostate Carcinoma, Prostate Adenocarcinoma With Neuroendocrine Differentiation, Stage IV Prostate Adenocarcinoma AJCC v7
- Interventions
- Cediranib, Olaparib
- Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 90 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2027
- U.S. locations
- 16
- States / cities
- La Jolla, California • Sacramento, California • San Diego, California + 9 more